Company Overview

Founded in 2008, Genosco is a clinical-stage biotechnology company pursuing the discovery and development of novel small-molecule drugs to treat patients with unmet medical needs.
We utilize a highly targeted approach with expertise in selective kinase inhibitors.
Currently, we have discovered several master scaffolds selectively inhibiting protein kinases which are enzymes that transfer phosphate groups to proteins and are key players in virtually all signal pathways.
There are about 518 kinases encoded in the human genome, many of them implicated in human diseases.
Our company consists of a highly interdisciplinary team of scientists with expertise in medicinal chemistry, structural and computational drug discovery design, cell biology, pharmacology and drug metabolism.
Our therapeutic areas include inflammation, autoimmune diseases and various types of cancers.